Table 1.
Summary of seven lines of treatment and a description of the radiologic features of the dominant right metastatic lung mass throughout treatment
| Therapy | Clinical trial (if applicable) | Cycles until progression | PFS ratio a | Radiologic features of dominant right lung mass | |
|---|---|---|---|---|---|
| Treatment response | Mass at progression | ||||
| Doxorubicin followed by olaratumab | NCT02326025 | 2 | — | No response | 4.0 cm nodule in largest dimension |
| Gemcitabine/docetaxel | — | 2 | 0.9 | No response | 6.2 cm soft tissue mass in largest dimension |
| Aldoxorubicin | NCT02049905 | 2 | 1.0 | No response | 8.0 cm soft tissue mass in largest dimension with extension into the chest wall |
| Pazopanib and topotecan | NCT02357810 | 7 | 5.1 | 8.1 × 7.6 cm cystic mass (previously solid); solid component decreased to 5.3 × 3.6 cm | 11.0 × 8.5 cm cystic mass with new destruction of anterior ribs and bronchopleural fistula |
| Trabectedin | — | 2 | 0.2 | No response | 11.4 × 9.7 cm cystic mass with increase in solid component extending through the chest wall |
| Temozolomide | — | 43 | 29.2 | Complete resolution of metastatic disease by cycle 9 with residual architectural changes and stable mediastinal lymphadenopathy | 7.6 × 1.8 × 4.4 cm soft tissue mass along surgical staple line |
| Atezolizumab | NCT02091141 | Ongoing with 22 previous cycles | — | Stable 5.0 × 1.1 cm soft tissue mass | n/a |
a
Progression‐free survival ratio indicating the time to progression on current treatment relative to time to progression on previous treatment.
Abbreviation: PFS, progression‐free survival.